Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medimetriks launches operations
The company is aggressively pursuing licensing opportunities, company and product acquisitions and initiating the development of a series of brands that will fill unmet needs in the marketplace.
The company is aggressively pursuing licensing opportunities, company and product acquisitions and initiating the development of a series of brands that will fill unmet needs in the marketplace.
The Custom III clinical trial was a 90-patient prospective study to assess the safety and efficacy of the Custom NX drug eluting stent system in patients with up
The AbsorbaTack 5mm absorbable tacks provide strong mesh attachment to the surrounding tissues, while reducing the amount of foreign material remaining in the patient long-term. According to the
The company’s revised new drug application (NDA) includes data from additional pharmacokinetic studies conducted by the company comparing CIP-Tramadol ER to Ultram ER. Subject to FDA acceptance for
The Biostat Disc Augmentation System consists of Biostat Biologx Fibrin Sealant, a human derived, biologic tissue sealant, and a proprietary application system designed to safely deliver the biologic
Akorn-Strides, is a joint venture that was formed in 2005 by Akorn and Strides Arcolab. Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said:
The Nanoset intellectual property acquisition includes over 15 issued patents and a number of patent applications covering various uses of nanomagnetic materials, including magnetic resonance imaging (MRI) image
Break study is a randomized, double-blind, placebo controlled study to assess the effect of six months of oral treatment with 400mg (200mg twice daily) alagebrium versus placebo in
This study is being carried out at the Memorial Sloan Kettering Cancer Center located in New York. This study is a component of an initial stage of at
The transaction is subject to customary closing conditions and is expected to close by June 30, 2008. The commercialized products acquired consist of the QuickCat thrombus aspiration catheter,